New antifungal drug shows promise against deadly fungal infections

NCT ID NCT05630976

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the safety and effectiveness of the antifungal drug isavuconazole as a first treatment for Chinese patients with serious invasive fungal infections caused by Aspergillus or other molds. All 70 participants received the drug for up to 84 days (or 180 days for certain infections). The main goal was to track side effects, while secondary goals included survival rates. The study is already completed.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Isavuconazole (also known as Cresemba), an antifungal drug
What this could lead to: If successful, this study could confirm that isavuconazole is a safe and effective first-line treatment for invasive fungal infections in Chinese patients.
What could go wrong: This is a single-arm, open-label study with no comparison group, so results may be less definitive. The small sample size (70 patients) and specific population may limit how well the findings apply to other groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

invasive aspergillosis Invasive Fungal Infections systemic mycosis Zygomycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INVASIVE FUNGAL DISEASE

Contacts and locations

Locations

Guangzhou First People's Hospital

Guangzhou, Guangdong, 510180, China
Henan provincial people's hospital

Zhengzhou, Henan, 450003, China
Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200040, China
Institute of Hematology, Chinese Academy of Medical Sciences

Tianjin, Tianjin Municipality, 300020, China
Jiading Central Hospital

Shanghai, 201800, China
Jieyang People's Hospital

Jieyang, Guangdong, 522095, China
Liaocheng people's Hospital

Liaocheng, Shandong, 252000, China
Peking University People's Hospital

Beijing, 100044, China
The First Affiliated Hospital Zhejiang University

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospital of Bengbu Medical College

Bengbu, 233000, China
The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 510120, China
The First Affiliated Hospital of USTC, Anhui Province Hospital

Hefei, Anhui, 230001, China
ZhuJiang Hospital of Southern Medical University

Guangzhou, Guangdong, 510280, China
Zibo Central Hospital

Zibo, Shandong, 255036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.